Abstract
The antiinflammatory effect of lipoproteins through neutralization of circulating endotoxin has questioned the safety of lipid-lowering drugs in chronic heart failure (CHF). We measured serum levels of interleukin-6, tumor necrosis factor (TNF)-alpha, and soluble TNF-alpha receptors 1 and 2 before and after 1-month treatment with pravastatin 40 mg in 58 patients with CHF. Short-term treatment with pravastatin attenuated the immune response in patients with CHF due to ischemic or nonischemic etiology.
Publication types
-
Clinical Trial
-
Comparative Study
MeSH terms
-
Aged
-
Case-Control Studies
-
Cytokines / drug effects*
-
Cytokines / metabolism
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Female
-
Follow-Up Studies
-
Heart Failure / diagnosis
-
Heart Failure / drug therapy*
-
Heart Failure / etiology
-
Humans
-
Inflammation Mediators / analysis*
-
Male
-
Middle Aged
-
Myocardial Ischemia / complications*
-
Myocardial Ischemia / diagnosis
-
Pravastatin / administration & dosage*
-
Probability
-
Prospective Studies
-
Receptors, Cytokine / drug effects*
-
Receptors, Cytokine / metabolism
-
Sensitivity and Specificity
-
Treatment Outcome
Substances
-
Cytokines
-
Inflammation Mediators
-
Receptors, Cytokine
-
Pravastatin